Hepatocellular carcinoma associated with the Hepatitis B virus and microRNA-155 expression | ||
| Microbial Biosystems | ||
| Article 17, Volume 10, Issue 3, September 2025, Pages 123-129 PDF (413.08 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mb.2025.356593.1243 | ||
| Authors | ||
| Rana T. Mohsen* 1; Hanan F. Salman2; Ola A. Kadhim1 | ||
| 1Department of Biotechnology, College of Science, University of Anbar, Al-Anbar, Iraq. | ||
| 2Department of Biology, College of Education for Women, University Of Anbar, Al-Anbar, Iraq. | ||
| Abstract | ||
| MicroRNA-155 (miR-155), identified as an oncogenic regulator in certain malignancies, is linked to tumor progression and aggressiveness. This cross-sectional observational study investigated miR-155 expression levels in plasma samples from hepatocellular carcinoma (HCC) patients with and without concurrent hepatitis B virus (HBV) infection. A cohort of 51 patients (aged 18–65 years) with histologically confirmed HCC was analyzed, stratified by HBV serostatus. Results demonstrated a 2.55-fold elevation in miR-155 expression in HBV-positive HCC patients compared to HBV-negative counterparts (p ≤ 0.001). These findings suggest miR-155 may serve as a prognostic biomarker and therapeutic target in HBV-associated HCC. Mechanistically, miR-155 exhibits oncogenic activity by suppressing tumor suppressor pathways. The HBV-encoded HBx protein is implicated in upregulating miR-155, potentially driving its sustained expression during hepatocarcinogenesis. Additionally, biochemical analyses revealed significantly elevated levels of hepatic injury markers including GPT, GOT, ALP, and indirect bilirubin in HBV-infected patients relative to healthy controls (p ≤ 0.001), further underscoring the interplay between viral infection, hepatic dysfunction, and miR-155 dysregulation. | ||
| Keywords | ||
| Hepatitis B virus; hepatocellular cancer; liver function; microRNAs; urea | ||
|
Statistics Article View: 933 PDF Download: 108 |
||
